Basilea Expects 2026 Operating Profit Of CHF 115 Mln

By Reuters News

- BASILEA PHARMACEUTICA AG, ALLSCHWIL BSLN.S:

  • RAISES FULL-YEAR GUIDANCE 2026 AND FINANCIAL TARGET FOR “AGENDA 2030” AND PROVIDES UPDATES ON LATE-STAGE CLINICAL PROGRAMS

  • 2026 OPERATING PROFIT EXPECTED TO REACH CHF 115 MILLION

  • RAISES FINANCIAL GUIDANCE FOR FY2026 AND CASH FLOW TARGET FOR 2026-2030

  • FY2026 RESEARCH AND DEVELOPMENT EXPENSES GUIDANCE CHF 125 MILLION; OPERATING PROFIT GUIDANCE CHF 115 MILLION

  • OUTLOOK 2026: EXPECTS TOTAL REVENUE AROUND CHF 310 MILLION

Further company coverage: BSLN.S

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.